We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

84 hedge funds and large institutions have $184M invested in Kalaris Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 26

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0.12% more ownership

Funds ownership: 1.7% → 1.81% (+0.12%)

0% more funds holding

Funds holding: 84 → 84 (0)

44% less capital invested

Capital invested by funds: $329M → $184M (-$145M)

Holders
84
Holders Change
–
Holders Change %
0%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
28
Reduced
26
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$12.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.82M
3
GC
GMT Capital
Georgia
+$4.04M
4
JP Morgan Chase
JP Morgan Chase
New York
+$1.44M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$1.1M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$5.62M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$3.38M
3
EOJOAM
E. Ohman J:or Asset Management
Sweden
-$1.18M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1,000K
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$816K
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$613K +$5.19K +26 +0.7%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$594K – – –
Swiss National Bank
28
Swiss National Bank
Switzerland
$572K +$51.3K +257 +7%
SB
29
Samsara BioCapital
California
$556K – – –
Lido Advisors
30
Lido Advisors
California
$536K – – –
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$476K +$185K +927 +43%
AA
32
ALPS Advisors
Colorado
$453K -$71.4K -358 -11%
Renaissance Technologies
33
Renaissance Technologies
New York
$358K +$461K +2,309 New
California State Teachers Retirement System (CalSTRS)
34
California State Teachers Retirement System (CalSTRS)
California
$291K -$27.9K -140 -7%
Man Group
35
Man Group
United Kingdom
$264K +$340K +1,702 New
UBS AM
36
UBS AM
Illinois
$205K – – –
PP
37
PDT Partners
New York
$204K +$262K +1,313 New
JF
38
Jump Financial
Illinois
$196K +$252K +1,261 New
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$194K +$8.78K +44 +4%
Two Sigma Advisers
40
Two Sigma Advisers
New York
$194K +$137K +687 +122%
Squarepoint
41
Squarepoint
New York
$190K +$112K +562 +85%
T. Rowe Price Associates
42
T. Rowe Price Associates
Maryland
$185K +$59.8K +300 +34%
CSS
43
Cubist Systematic Strategies
Connecticut
$183K +$50.9K +255 +28%
Deutsche Bank
44
Deutsche Bank
Germany
$172K -$7.78K -39 -3%
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$171K -$18.6K -93 -8%
CS
46
Credit Suisse
Switzerland
$164K +$14.4K +72 +7%
Tudor Investment Corp
47
Tudor Investment Corp
Connecticut
$163K -$4.99K -25 -2%
Osaic Holdings
48
Osaic Holdings
Arizona
$160K – – –
Bank of America
49
Bank of America
North Carolina
$158K -$754K -3,779 -79%
DekaBank Deutsche Girozentrale
50
DekaBank Deutsche Girozentrale
Germany
$156K +$17.4K +87 +10%
1
2
3 4

KLRS Hedge Fund Activity: Q1 2022 in Review

84 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2022, worth a combined $184M — down 44% from $329M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KLRS positions and 14 closed out — a net gain of 1 holder — while 28 added to existing stakes and 26 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $12.5M. The largest seller was State Street, cutting an estimated $5.62M.

  • 84 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $184M of Kalaris Therapeutics stock for Q1 2022, down 44% quarter-over-quarter.
  • 15 funds opened new Kalaris Therapeutics positions in Q1 2022 and 14 closed out, a net change of +1 holder.
  • The largest Kalaris Therapeutics buyer in Q1 2022 was RA Capital Management, an estimated $12.5M added.
  • The largest Kalaris Therapeutics seller in Q1 2022 was State Street, an estimated $5.62M sold.

Based on aggregated 13F filings for Q1 2022.